Formulation, Optimization, and Evaluation of Lornoxicam-Loaded Novasomes for Targeted Ulcerative Colitis Therapy: In Vitro and In Vivo Investigations
Journal of drug targeting,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 21
Published: Jan. 20, 2025
The
purpose
of
this
work
was
to
create
and
assess
Lornoxicam
(LOR)
loaded
Novasomes
(Novas)
for
the
efficient
treatment
ulcerative
colitis.
study
performed
using
a
23
factorial
design
investigate
impact
several
formulation
variables.
Three
separate
parameters
were
investigated:
Surface
Active
agent
(SAA)
type
(X1),
LOR
concentration
(X2),
SAA:
Oleic
acid
ratio
(X3).
dependent
responses
included
encapsulation
efficiency
(Y1:
EE
%),
particle
size
(Y2:
PS),
zeta
potential
(Y3:
ZP),
polydispersity
index
(Y4:
PDI).
vesicles
demonstrated
remarkable
efficiency,
ranging
from
81.32
±
3.24
98.64
0.99%.
vesicle
sizes
ranged
329
9.88
583.4
9.04
nm
with
high
negative
values.
release
pattern
Novas'
biphasic
adhered
Higuchi's
model.
An
in-vivo
assessed
how
LOR-Novas
affected
rats'
acetic
acid-induced
colitis
(UC).
optimized
effectively
reduced
colonic
ulceration
(P
<
0.05)
inflammatory
pathway
via
inhibiting
Toll-like
receptor
4
(TLR4),
Nuclear
factor
kappa
β
(NF-κβ)
inducible
nitric
oxide
(iNO).
At
same
time,
it
elevated
Silent
information
regulator-1(SIRT-1)
glutathione
(GSH)
colon
contents.
Thus,
current
suggested
that
LOR-
Novas
may
be
viable
Language: Английский
An Overview on the Role of Ionic Liquids and Deep Eutectic Solvents in Oral Pharmaceuticals
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(3), P. 300 - 300
Published: Feb. 25, 2025
Over
the
past
twenty
years,
ionic
liquids
(ILs)
and
deep
eutectic
solvents
(DESs)
have
gained
recognition
across
various
fields,
including
catalysis,
extraction
purification,
materials
science,
biotechnology.
Notably,
use
of
ILs
DESs
in
pharmaceutical
research,
especially
drug
delivery,
has
seen
remarkable
expansion
over
decade.
This
review
offers
a
comprehensive
analysis
specifically
designed
for
oral
administration
drugs
having
unfavorable
biopharmaceutical
properties.
The
classification
characteristics
DESs,
along
with
their
newer
natural
(Bio-ILs
NaDESs)
therapeutic
subcategories
(API-ILs
TheDESs)
are
outlined.
Additionally,
further
subgroup
ILs,
known
as
surface
active
(SAILs),
is
described.
Then,
detailed
examination
available
manufacturing
methods
sustainable,
time-consuming,
scalable
perspective,
toxicity
concerns
relation
to
subdivision
evaluated.
Finally,
specific
applications
whether
used
neat
or
converted
into
administrable
dosage
forms,
analyzed
discussed.
Despite
significant
advancements
recent
years
regarding
these
there
still
many
aspects
that
need
investigation.
These
include
interaction
biological
systems
(gastrointestinal
fluids
mucosa),
long-term
stability,
development
effective
delivery
systems.
Language: Английский